JSW
CYTK icon

Journey Strategic Wealth’s Cytokinetics CYTK Stock Holding History

Journey Strategic Wealth’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$215K Buy
3,262
+79
+2% +$5.02K 0.01% 731
2025
Q4 		$202K Buy
+3,183
New +$198K 0.01% 717
2024
Q1 		– Sell
-2,914
Closed -$243K – 318
2023
Q4 		$243K Buy
+2,914
New +$106K 0.01% 170

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Journey Strategic Wealth's CYTK Position: Q1 2026 in Review

Journey Strategic Wealth increased its Cytokinetics (CYTK) stake by 2.5% in Q1 2026, buying an estimated $5.02K and bringing the position to 3,262 shares worth $215K. The position accounts for 0.01% of the portfolio, ranked #731.

Journey Strategic Wealth first reported a position in CYTK in Q4 2023 and has held it in 3 quarters since. The position peaked at $243K in Q4 2023. 440 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Journey Strategic Wealth held 3,262 shares of Cytokinetics worth $215K as of Q1 2026.
  • Journey Strategic Wealth bought 79 Cytokinetics shares in Q1 2026, an estimated $5.02K.
  • Cytokinetics made up 0.01% of Journey Strategic Wealth's portfolio in Q1 2026, its #731 holding.
  • Journey Strategic Wealth first reported a position in Cytokinetics in Q4 2023 and has held it in 3 quarters since.
  • Journey Strategic Wealth's Cytokinetics position peaked at $243K in Q4 2023.
  • 440 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Journey Strategic Wealth's 13F filing for Q1 2026, filed 15 Apr 2026.